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lytic myofibers (IIb + IIx), and an overall decrease in capillary density was observed in
CSQ/CHF mice compared to WT littermates. Analysis of fiber type-specific capillary den-
sity revealed an increase in type IIa myofiber capillary density and a concomitant
decrease in type IIb + IIx myofiber capillary density in the CSQ/CHF mice. Conclusion.
These results suggest that chronic heart failure causes skeletal muscle fiber type switch-
ing and dysregulation of angiogenesis in a fiber type-specific manner. Furthermore,
these results support the use of the CSQ/CHF mouse model to further study the role of
skeletal muscle maladaptation in chronic heart failure and to explore potential therapeutic
targets.
1045-197 Evidence for Hypoxia and Hypoxia-Inducible Factor-1-
Alpha Mediated Vascular Endothelial Growth Factor 
Expression in Lipid-Rich Plaque Macrophages as Link 
Between Inflammation and Angiogenesis
Randolph Hutter, Carolina Valdiviezo, Bernhard Sauter, Roberto Corti, Gurusher 
Panjrath, Francine Carrick, John T. Fallon, Valentin Fuster, Juan Jose Badimon, Mount 
Sinai School of Medicine, New York, NY
Background: Macrophages expressing the pro-angiogenic factor VEGF can contribute to
plaque progression and vulnerability via induction of intimal neovascularization. Hypoxia
Inducible Factor 1-alpha (HIF-1 alpha) has been identified as key transcriptional regulator
of cellular VEGF-synthesis and mediates the angiogenic response of tissues to hypoxia.
However, little is known about the pattern of expression of HIF-1 alpha in atherosclerosis.
Our objective was to assess in parallel the expression of HIF-1 alpha and VEGF in
human and experimental atherosclerosis comparing lipid-rich with fibrous plaque.
Methods: In human atheroma (n=12) HIF-1 alpha and VEGF mRNA and protein expres-
sion were evaluated by in situ hybridization and immunohistochemistry (data presented
as mean±SEM). In NZW-rabbits (n=14) atherosclerotic lesions were induced by aortic
double balloon injury and 9 months of high-cholesterol (HC) diet. Five rabbits were sacri-
ficed at 9 months and were used as baseline (BL). The remaining rabbits were then ran-
domized into continued HC diet (n=5) and normal chow diet (ND) (n=4) for another 6
months. Total serum cholesterol at the end of ND treatment was 27±10 mg/dl vs.
861±143 mg/dl at BL (P<.01) and 526±108 mg/dl with continued HC-diet at 15 months
(P<.01).
Results: In human atheroma, HIF-1 alpha and VEGF mRNA and protein expression were
increased in lipid-rich compared to fibrous plaque (23±5 % vs. 5±2 %, P<.01; 32±6 % vs.
8±3 %, P<.05) and correlated with high macrophage and neovessel content (P<.05).
Double-labeling demonstrated co-localization of HIF-1 alpha and VEGF in inflammatory
cells surrounding intimal neovessels in close proximity to cholesterol clefts. In plaques of
rabbits with continued HC diet and high serum lipid levels expression of both HIF-1 alpha
and VEGF-protein as assessed by immunohistochemistry and Western Blot were signifi-
cantly increased compared to BL and ND.
Conclusions: The selective detection of HIF-1 alpha in VEGF-expressing macrophages
located in lipid-rich plaque tissue points to hypoxia as a possible link between inflamma-
tion and angiogenesis. Both processes might synergistically contribute to plaque pro-
gression and vulnerability.
1045-198 Influence of Diabetes Mellitus on Coronary Collateral 
Flow: A Definite Answer to a Rather Elderly Controversy
Rainer Zbinden, Stefan Zbinden, Michael Billinger, Stefan Windecker, Bernhard Meier, 
Christian Seiler, Cardiovascular Center Bern, Bern, Switzerland
Background: The influence of diabetes mellitus (DM) on coronary collateral flow is con-
troversial. This may be due to the use of inaccurate means of measuring collateral flow
(i.e. angiographic assessment), another reason relates to differences in parameters influ-
encing collateral flow between diabetic and nondiabetic patients (serum lipids, severity of
coronary artery disease (CAD)). The purpose of this study was to determine the influ-
ence of DM on coronary collateral flow in a large population with variable degrees of CAD
using accurate means of collateral flow measurement.
Methods: 187 patients (age 63 +/- 9 years; 86 diabetic and 101 nondiabetic patients)
were included in the study. Coronary collateral flow was assessed in 196 stenotic and in
38 angiographically normal vessels using a pressure guide wire (n=145), Doppler guide
wire (n=53) or both (n=36) to calculate pressure- or flow-velocity-derived collateral flow
index (CFI). Diabetic patients were matched for gender, age, serum lipids and percent
diameter stenosis of the vessel undergoing CFI measurement with a nondiabetic control
group.
Results: The two groups were exactly balanced for clinical and angiographic data. There
was no difference between CFI in the diabetic versus the non-diabetic patients (0.205 ±
0.119 and 0.217 ± 0.128; p=NS). There was still no difference in CFI when only angio-
graphically normal vessels (0.193 ± 0.084 and 0.201 ± 0.072; p=NS) or chronic total cor-
onary occlusions (0.314 ± 0.151 and 0.323 ± 0.186; p=NS) were compared. There was a
trend towards a lower number of patients having angina pectoris during the one-minute
vessel occlusion in the diabetic group (p = 0.1). There was no correlation between the
CFI and the level of HbA1c (as marker for blood glucose control over the last 2-3
months).
Conclusion: There is no difference in coronary collateral flow between diabetic and non-
diabetic patients. There is no inverse “dose-response” relation between blood glucose
control (represented by the HbA1c level) and coronary collateral flow. There is a trend
that diabetic patients have less angina pectoris during a one minute balloon occlusion
than non-diabetic patients.
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1046-165 Measurement of Resting Ankle Brachial Index May Not 
Accurately Identify Disease in Patients With Signs or 
Symptoms of Peripheral Arterial Disease
Ingrid Hriljac, Jeffrey W. Olin, Victoria Teodorescu, Susan M. Gustavson, Jonathan L. 
Halperin, Mount Sinai Medical Center, New York, NY
Background: The ankle-brachial index (ABI) is useful for objective assessment of lower
extremity arterial perfusion, correlating with symptoms and functional severity of periph-
eral arterial disease (PAD) in population-based studies. This simple, inexpensive mea-
surement can be performed in the primary care office for detection of PAD, and is a
marker of increased cardiovascular risk in both symptomatic and asymptomatic patients.
The diagnostic accuracy of the resting ABI in patients with symptoms or signs of PAD,
however, has not been determined. Methods: In order to determine the added diagnostic
utility of measuring ABI and pulse volume waveforms (PVR) at rest and after exercise, we
analyzed the results of 142 consecutive patients who were referred to the vascular labo-
ratory by non-vascular specialists between February and September 2003. Results: The
average patient age was 68 years; 54% were male. Resting ABI was normal in 44%,
abnormal in 38% and not diagnostic due to arterial calcification in 17%. Forty percent
were abnormal in those with claudication, 45% in those with ulceration and 28% in those
with rest pain. Thirty-six (57%) patients with a normal ABI underwent treadmill exercise
testing and 28% of these were found to have an abnormal exercise study indicating the
presence of PAD. Among the 24 patients (17%) with calcified vessels, 5 (21%) had
abnormal PVR consistent with PAD. Conclusion: In symptomatic patients with normal
resting ABI, PAD was diagnosed frequently by measuring ABI after exercise. Of the 17%
in whom arterial calcification precluded accurate ABI measurement, PVR disclosed PAD
in 21%. In patients with suspected PAD, referral to a vascular laboratory for exercise test-
ing and PVR offers more precise diagnosis than office measurements of ABI.
1046-166 Is the Application of Collagen-Based Vascular Closure 
Devices After Percutaneous Coronary Interventions 
Safe and Effective? Intermediate Results From the 
Prospective Bad Berka Registry
Marc-Alexander Ohlow, Hügl Burkhard, Karsten Reinig, Hubertus von Korn, Bernward 
Lauer, Zentralklinik Bad Berka, Bad Berka, Germany
Background: Several vascular closure devices (VCD) were developed as an alternative
for manual compression after percutaneous interventions (PCI) of the coronary arteries
to reduce the time to discharge. We report about the results of the collagen based VCD
VasoSeal®ES™ (Datascope Corp.) [VS] and Angio-Seal® (St. Jude Medical) [AS].
Methods: From 10/01 to 09/02 patients with collagen based VCD after percutaneous
interventions were enrolled in our prospective registry. During the intervention heparin,
aspirin and if necessary clopidogrel were administered. The two VCD were used accord-
ing to a standardized method, the choice of the device after PCI was left to the discretion
of the investigator. Secondary haemorrhage, haematomas (> 5 cm diameter), pseudoan-
eurysms and AV fistulae were noted as complications. A clinical examination and a
Duplex examination in addition was performed routinely at every patient.
Results: 5717 cardiac catheterisations were done until deadline 31.09.2002.
In 1170 cases a VCD was used after coronary intervention, 700 times AS and 470 times
VS. One of the above described complications appeared at 54 of 700 cases (7.71%) in
the AS group, in the VS group in 35 of 470 cases (7.44 %.) The predominant number of
the complications fell on minor complications such as haematoma and smaller secondary
haemorrhages (49 of 54 at AS group (7%) and 30 of 35 at VS group (6,4%). Only 5 of 54
(0,7%) of AS and in 5 of 35 (1%) of VS developed more serious complications. One
patient in the AS group developed an AV fistula, in four cases we saw pseudoaneurysms.
5 cases of the VS group developed pseudoaneurysms. All aneurysms could be success-
fully compressed in an ultrasound guided procedure. In one patient of the VS group the
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collagen plug was placed intravascular, surgical repair because of haematomas was
needed once in the VS group and twice in the AS group respectively. There were no sig-
nificant difference between the two devices in terms of total complications.
Conclusion: The application of collagen based VCD after PCI does not increase the rate
of complications and can be safely and effectively performed. The complication rates are
equivalent to previously published rates with manual compression.
1046-167 Incidence and Predictors of Left Ventricular 
Dysfunction in Patients With Takayasu or Giant Cell 
Aortitis
David H. Pfizenmaier, II, Faisal O. Al Atawi, Yamil Castillo, Krishnaswamy 
Chandrasekaran, Leslie T. Cooper, Mayo Clinic, Rochester, MN
Background: Left ventricular dysfunction (LVD) in patients with aortitis has been
described in few studies. The incidence and predictors of LVD in patients with angio-
graphically confirmed Takayasu or Giant Cell aortitis (TA/GCA) is not known.
Methods: We identified 87 patients with angiographically confirmed TA/GCA. All patients
underwent transthoracic echocardiographic studies that were subsequently reviewed in a
blinded fashion. LVD was defined as an ejection fraction (LVEF) less than 50%.
Results: The study population was 84 % Caucasian (73/87), 91 % female (79/87), and
had a mean age of disease onset of 30 years. The average LVEF was 56.5 % (n=87).
The average time between symptom onset and diagnosis was 40 months, and the aver-
age time between symptom onset and echocardiography was 81 months. Of the 87
patients, 19.5% (17) had an LVEF less than 50 % (mean of 37 % +/- 7.9 %). LVD was
present in 43 % (10/23) of patients with versus 11 % (7/64) of patients without aortic arch
involvement (p = 0.0017). LVD was found in 27 % (12/44) of patients with versus 12 % (5/
43) of patients without descending aortic involvement (p=0.07). Aortic regurgitation was
present in 76 % (13/17) of patients with versus 36 % (25/70) of patients without LVD
(p=0.002). Patients with LVD had a median of 2 (range 1-4) involved aortic segments
compared to a median of 1 (range 1-4) among those without LVD (p=0.008). The follow-
ing factors were not associated with the presence of LVD: aortic thickness, the number of
involved extra-aortic vessels, aneurysm, hypertension, diabetes, tobacco use, sedimen-
tation rate, leukocyte count, hemoglobin, retinopathy, and progressive course of arteritis.
Conclusion: In TA/GCA with aortitis, LVD was associated with aortic regurgitation, aortic
arch involvement, and with the greater extent of aortic involvement. Descending aortic
arch involvement was associated with LVD with borderline significance. These data sug-
gest that hemodynamic and immunologic factors both contribute to LVD in this popula-
tion.
1046-168 Global Renal Revasculatization Preserves Renal 
Function in Diabetic and Nondiabetic Patients With 
Renal Insufficiency
Srinivasa P. Potluri, Rajesh Subramanian, Jose A. Silva, Stephen R. Ramee, Tyrone J. 
Collins, James Stephen Jenkins, Christopher J. White, Ochsner Clinic Foundation, New 
Orleans, LA
Background: Patients with diabetes and ischemic nephropathy progress to end stage
renal disease at a faster rate compared to non-diabetic patients. Whether diabetic
patients (DM) obtain similar benefits in renal function preservation as non-diabetic
patients (NDM) with renal artery stenting is unknown.
Methods: The renal function of 46 consecutive patients with bilateral renal stenosis or
solitary renal artery stenosis (13 DM; 33 NDM) and renal insufficiency (serum creatinine
1.5 to 4.0mg/dl) were analyzed for blood pressure, number of medications, and by con-
structing the pre and Post procedures 1/creatinine over time slopes for all patients.
Results: All patients had deterioration of renal function prior to intervention. At a mean
follow-up of 23 months post intervention, the slope of reciprocal of creatinine over time
showed improvement in both groups. (Figure)
Conclusion: Renal artery stenting is equally beneficial in preservation of renal function in
DM and NDM patients with impaired renal function and atherosclerotic global renal artery
stenosis. 
1046-169 Renal Artery Stenting for Blood Pressure Control Is 
Equally Effective in Unilateral and Bilateral Renal Artery 
Stenosis
Khaldoon Alaswad, Tyrone J. Collins, Stephen J. Ramee, James Stephen Jenkins, 
Christopher J. White, Ochsner Clinic Foundation, New Orleans, LA
Introduction: Hypervolemia is the pathophysiology of bilateral renal artery stenosis (RAS)
while hyper-reninemia is the pathophysiology of unilateral RAS in patients with renovas-
cular hypertension. It is not known if bilateral stenting for bilateral RAS is similar to unilat-
eral stenting for unilateral RAS.
Methods: We reviewed the blood pressure (BP) at baseline and one month in 176 con-
secutive patients: after unilateral stenting in 110 patients with unilateral RAS and bilateral
stenting in 66 patients with bilateral RAS. All treated arteries had > 50% atherosclerotic
stenosis by angiography. All patients had uncontrolled hypertension despite therapy with
two or more BP medications. Patients with a solitary (single) kidney, on dialysis, or kidney
transplant were excluded.
Results: BP, renal function, and demographics were similar at baseline. One month fol-
lowing renal intervention, both groups demonstrated similar improvement in BP (see
table. Note: *p <0.0001, †p=0.017 compared to baseline).
Conclusion: The BP response after renal stent placement is significant and similar in
magnitude in patients with bilateral vs. unilateral RAS.
1046-170 Surgical Treatment of Ascending Aortic Aneurysms in 
Patients With Giant Cell Aortitis
Alok Mathur, Kenton J. Zehr, Thomas A. Orszulak, Charles J. Mullany, Hartzell V. Schaff, 
Mayo Clinic, Rochester, MN
Background: Giant cell aortitis (GCA) is a rare cause of an ascending aortic aneurysm.
We present an 8 year experience with surgical repair.
Methods: 37 pt (29:8M, age 69.6+/-9.5 years) were operated from 1995-2002. 27%(10)
had a history of steroid treatment for temporal arteritis or polymyalgia rheumatica, 8.9+/-
3.9 years prior. 51%(19) patients had +3-+4 aortic regurgitation. Maximal aneurysm size
was 6.1+/-0.8 cm. 81%(30) underwent replacement of the ascending aorta, 11%(4) had
a modified Bentall procedure, 5%(2) had a valve-sparing root reconstruction, and 3%(1)
had aortorrhaphy. 59(22) required 22+/-9 minutes of hypothermic circulatory arrest for
hemi or complete aortic arch repair. 70%(26) pt had concomitant procedures.
Results: There was no early mortality. Morbidity was re-exploration for bleeding in 8%(3),
stroke in 8% (3), left vocal cord paralysis in 5%(2), renal failure in 5%(2), and GI bleed in
3%(1). 32%(19) received postoperative steroid therapy. Mean follow-up was 2.8+/-2.3
years. 4-year survival was 74% (95%CI 57-94). Other descending and/or abdominal aor-
tic or great vessel aneurysms occurred in 46%(17). 4 had prior aneurysm surgery, 8 were
followed with aneurysms, and 5 underwent repair of an aneurysm in the follow-up period.
Of 8 late deaths, 3 were caused by complications of a descending thoracic aneurysm.
Conclusions: Ascending aortic aneurysms caused by GCA can involve the aorta from the
aortic root through the aortic arch. A tailored operative intervention can be done with low
morbidity and mortality. Other aneurysms of the aorta and great vessels occur in nearly
one-half of patients. Frequent surveillance of the remaining aorta is mandatory.
1046-171 Preoperative Statins Are Associated With Shorter 
Length of Stay and Improved Long Term Survival in 
Patients Undergoing Vascular Surgery
R. Parker Ward, Nicholas J. Leeper, James N. Kirkpatrick, Kim A. Williams, Roberto M. 
Lang, Lewis B. Schwartz, Tina R. Desai, University of Chicago, Chicago, IL
Background: Patients (pts) undergoing vascular surgery are at risk for perioperative car-
diovascular (CV) complications. Preoperative statin therapy has recently been associated
with decreased perioperative mortality in pts undergoing vascular surgery. Our goal was
to study the effect of preoperative statin therapy on perioperative morbidity, length of stay
(LOS), and long-term survival in pts undergoing vascular surgery. Methods: We retro-
spectively reviewed 561 consecutive infra-inguinal vascular surgeries on 446 pts
between 1995-2001. Preoperative statin and beta-blocker use, comorbidities, periopera-
tive events, and LOS were noted. Long-term survival was assessed using the Social
Security Death Index (SSDI). Results: Preoperative statins and beta-blockers were used
in 16% and 23% of surgeries, respectively. Baseline comorbidities included: CAD (59%),
CABG (19%), DM (54%), prior stroke (CVA) (5%), smoking (55%), HTN (76%), COPD
(8%), and ESRD (18%). Perioperative events included 30-day death (2.9%), 30-day CV
death (2.0%), MI (5.2%), CVA (0.9%), and major vascular events (13.4%). Statin therapy
was associated with a shorter LOS (6.4 vs 9.7 days, p<0.0001), while beta-blocker ther-
apy was not. Multivariate analysis models, adjusting for multiple surgeries within pts, and
controlling for comorbidities, age, and operative year, were employed. Independent pre-
dictors of shorter LOS were statin therapy (p=.008), absence of ESRD (p= 0.01), and
later operative year (p=0.02). Beta-blocker therapy was associated with fewer MI’s
(p=0.02), and fewer combined CV death, MI and CVA (p=0.04). Statin therapy was asso-
ciated with trends towards fewer MIs (p=0.09), and fewer combined death, MI, and CVA
Unilateral 
Baseline (n=110)
Unilateral Follow-
up (n=110)
Bilateral 
Baseline 
(n=66)
Bilateral Follow-
up (n=66)
SBP, mmHg 169±28 147±23* 172±32 148±26*
DBP mmHg 87±15 77±13* 87±15 77±13*
Mean BP 
mmHg
114±17 100±14* 115±19 101±16*
Number of 
BP Meds
2.43±0.97 2.10±0.86† 2.28±1.26 1.94±1.14
